Posted on 12/07/2010 in Pharmaceutical Company Product News Daiichi Sankyo has published data from a new clinical trial, illustrating the efficacy of its drug edoxaban when compared to enoxaparin.
According to results from the phase III study, Daiichi Sankyo's drug proved superior to the alternative in terms of preventing venous thromboembolic events in patients who have undergone total knee replacement surgery.
It means the treatment was able to meet its primary efficacy endpoint, with the data set to support the company's currently-pending applications for regulatory approvals of the drug.
Dr Takeshi Fuji, head of orthopaedic surgery at Osaka Koseinenkin Hospital, said the superior performance of edoxaban to the current standard of care represents an "encouraging" outcome.
He added: "The combination of efficacy, tolerability and convenient once-daily oral dosing in this clinical setting further supports the potential role of edoxaban in helping patients and physicians avoiding thrombotic events."
Earlier this year, Daiichi Sankyo announced the nomination of Joji Nakayama to become its new president and chief executive officer, replacing the role's current occupant Takashi Shoda.Other news stories from 12/07/2010
Read more in the Zenopa News Archive
How this news is generated
|
